Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 29, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 540,000 Ordinary shares of 25 pence each.
- Purchase Date: February 29, 2012.
- Price Range: Highest price paid was 1,411.0 pence per share; lowest price paid was 1,392.0 pence per share.
- Treasury Holdings (Settled): 506,782,927 shares (9.12% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,567,927 shares (10.07% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,049,482,646 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 540,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 10.07% when including unsettled purchases. The filing does not provide comparative financial data for prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. The transaction is noted as being in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (506,782,927 settled) against the company's latest annual report.
- Confirm the calculation of total voting rights (10.07% held in Treasury including unsettled shares).
- Check the current market price of GSK shares to compare against the repurchase price range (1,392.0 to 1,411.0 pence).
- Review the remaining authorization for share buybacks under the May 5, 2011 shareholder mandate.